Joseph H Zielinski

US Patent:

20100166865, Jul 1, 2010

Filed:

Aug 15, 2007

Appl. No.:

12/376458

Inventors:

Saran Kumar - Edison NJ, US
Wen-Chung Shieh - Berkeley Heights NJ, US
Seema Tomer - Parsippany NJ, US
Joseph Lawrence Zielinski - Florham Park NJ, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 31/675
A61K 9/14
A61P 35/00

US Classification:

424486, 514 94, 977773, 977915, 977906

Abstract:

A method of Nanoparticle-based therapy for a mammalian subject is disclosed. The method uses Nanoparticles and/or Nanoparticles with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made up of polymer chains either covalently linked or surface adsorbed to the polymer components. After a desired Nanoparticle biodistribution is achieved, the affinity agent binds to the target surface and helps internalize the Nanoparticles

US Patent:

20100267787, Oct 21, 2010

Filed:

Nov 10, 2008

Appl. No.:

12/741857

Inventors:

Gregory Harasymiw - Morristown NJ, US
Wayne Talamonti - Kunkletown PA, US
Robert Frank Wagner - Hillsborough NJ, US
Joseph Lawrence Zielinski - Florham Park NJ, US

International Classification:

A61K 31/41
A61P 9/10
A61P 9/12
A61P 9/04

US Classification:

514381

Abstract:

Provided are compositions comprising aqueous solutions of valsartan suitable for oral administration, preferably in pediatric and geriatric populations. Methods for making such compositions and methods for their stabilization are provided.

US Patent:

20120263791, Oct 18, 2012

Filed:

Dec 21, 2010

Appl. No.:

13/518027

Inventors:

Joseph L. Zielinski - Florham Park NJ, US
John Vrettos - Union NJ, US
Qin Ji - Randolph NJ, US
Subash Patel - Somerville NJ, US

Assignee:

NOVARTIS AG - BASEL

International Classification:

A61K 9/28
A61P 25/00
A61K 31/517

US Classification:

424474, 5142663, 51426623

Abstract:

The present invention relates to pharmaceutical formulations comprising a 1H-quinazoline-2,4-dione AMPA receptor antagonist. More particularly, the invention relates to immediate release formulations comprising such a compound.